| Event Value | ₹12.47 CrPreferential Issue |
|---|---|
| Market Cap | ₹203.95 CrSmall Cap |
| Revenue TTM | ₹135.73 CrOperating Income |
| RSI | 46.24Neutral Zone |
| Deal value | ₹12.47 Cr |
| Share of market cap | 6.1% |
Key highlights
- The number of equity shares to be issued was revised from 7,20,000 to 6,55,000
- Shares are priced at ₹190.37 each, including a premium of ₹180.37 over face value
- The total value of the fund raise through debt adjustment is ₹12.47 crore
- Post-allotment shareholding of Katra Holding will increase to 9.41 percent from 4.85 percent
- Subscription money will be adjusted against an existing unsecured loan of ₹26.41 crore
Details of the Preferential Issue
Kerala Ayurveda Limited has modified its 34th Annual General Meeting notice to reflect changes in its capital raising plans. The company intends to issue up to 6,55,000 equity shares with a face value of ₹10 each to Katra Holding Private Limited. The issue price is fixed at ₹190.37 per share, determined in accordance with SEBI ICDR Regulations.
This pricing represents a significant premium over the face value and is based on the higher of the 90-day or 10-day volume-weighted average price. The total allotment value of approximately ₹12.47 crore is specifically designed to stay within the 5 percent threshold of post-issue share capital to comply with SEBI Takeover Regulations.
Strategic Rationale and Use of Proceeds
The proposed allotment serves as a debt-to-equity conversion mechanism rather than a fresh cash infusion. The company is adjusting its existing unsecured loan obligations of ₹26.41 crore owed to Katra Holding Private Limited. By converting ₹12.47 crore of this debt into equity, Kerala Ayurveda aims to strengthen its balance sheet and improve its debt-to-equity ratio.
This move is expected to increase the net worth of the company and reduce its interest burden, providing greater financial flexibility for its traditional wellness and pharmaceutical operations. No other directors or key managerial personnel are participating in this specific preferential offer.
Financial and Market Context
- The company reported a TTM net loss of ₹26.52 crore despite annual revenue growth of 19 percent
- Operating revenue for the latest quarter stood at ₹33.19 crore with a negative profit margin
- The stock has witnessed a 64.44 percent decline over the past year, currently trading at ₹169.5
- Promoter holding prior to the issue stands at 35.61 percent with 20.35 percent of that stake pledged
- The current Piotroski Score of 2 indicates weak financial health and operational efficiency
Business and Industry Overview
Kerala Ayurveda is a legacy player in the Ayurvedic healthcare sector, operating across a wide spectrum including wellness clinics, hospitals, and herbal products. The company maintains a presence in India and international markets, focusing on authentic traditional medicine research. The Indian Ayurveda market is experiencing a transition toward organized wellness services, supported by increasing consumer awareness and government initiatives under the AYUSH ministry.
For Kerala Ayurveda, deleveraging through promoter equity participation is a critical step in stabilizing its capital structure amid a challenging period for its bottom-line performance.
| Share price | ₹169.5 |
|---|---|
| Market capitalisation | ₹203.95 Cr |
| Revenue (annual) | ₹131.15 Cr |
| Net profit (annual) | -₹16.56 Cr |
| Revenue (latest quarter) | ₹33.19 Cr-4.44% vs previous quarter |
| Net profit (latest quarter) | -₹7.98 Cr-2.77% vs previous quarter |
| P/E (TTM) | -7.69×Sector 50.43× |
| Promoter holding | 35.61%0.00% QoQ |
| FII holding | 0.17%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Kerala Ayurveda Limited announcing a corrigendum to the AGM notice regarding a revised preferential issue of equity shares. Market figures from a third-party data provider.
